Robotic knee surgery
This article was originally published in The Gray Sheet
Executive Summary
Curexo Technology submits 510(k) application for use of its Robodoc robotic surgical system to prepare knee joints for replacement. Robodoc allows surgeons to preoperatively plan total knee arthroplasty procedures in a 3-D virtual space and then perform the surgery exactly as planned on the patient's knee. The robotic surgical system gained 510(k) clearance for use in total hip arthroplasty in August and has been used in over 24,000 surgical procedures worldwide to date (1"The Gray Sheet" Aug. 25, 2008, In Brief)
You may also be interested in...
Financings In Brief
Sequenom grosses $51.6 million for diagnostics development: Firm will gross $51.6 million through the sale of 12.4 million shares of its stock at $4.15 each to "certain investors" under an agreement announced May 12. The private placement is expected to close May 17. Proceeds will be used for R&D and product commercialization efforts. The San Diego firm says it expects launch a noninvasive, laboratory-developed DNA test for Down syndrome (Trisomy 21) by the end of 2011 and file a PMA application for the test by the end of 2012. Sequenom also is aiming to launch a laboratory-developed test for age-related macular degeneration in the first half of 2011. Jefferies & Company and Lazard Capital Markets were placement agents for the stock offering
Curexo’s DigiMatch Robodoc
Image-directed robotic surgical system gains 510(k) clearance to prepare hip joints for replacement. The system allows surgeons to select "an ideal implant from multiple implant manufacturers after reviewing a detailed CT scan," Curexo says. Robodoc is the first active robotic system cleared for orthopedic surgery, the Sacramento, Calif., company claims. Curexo acquired the technology in 2007 with the assets of Integrated Surgical Systems
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.